A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
← catalyst calendarNCT02724228 · readout ≤ 498 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30actual
Sites
9
Countries
Australia, France, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-01-26 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2016-03-31 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Intervention
- Drug: BMN 111 — also filed as Modified recombinant human C-type natriuretic peptide, Vosoritide
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured Until near final adult height is reached, and up to at least 16 years of age for females and 18 years of age for males, whichever occurs later
Publications
- PMID 38649657 — linked by the registry
- PMID 31269546 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed